Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31094168 | 0.94 | REN (0.38) | NMBRSIRT2REN | |
| SCHEMBL29475292 | 0.90 | NMBR (0.40) | NMBRSIRT2REN | |
| SCHEMBL30065645 | 0.88 | SIRT2 (0.40) | NMBRSIRT2RENKLK7 | |
| SCHEMBL30096878 | 0.84 | REN (0.37) | REN | |
| SCHEMBL30524340 | 0.84 | PSEN1 (0.37) | NMBRSIRT2REN | |
| SCHEMBL34461946 | 0.84 | REN (0.39) | REN | |
| SCHEMBL31210152 | 0.83 | PSMB8 (0.37) | REN | |
| SCHEMBL30343346 | 0.83 | PSEN1 (0.36) | NMBRREN | |
| SCHEMBL30250211 | 0.83 | OPRD1 (0.36) | — | |
| SCHEMBL34461945 | 0.82 | REN (0.40) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655312-A1 | A PROCESS FOR THE PREPARATION OF GLUCAGON | Biocon Limited (IN) | 2025-12-03 | — | — | EP | claimed |
| WO-2024157198-A1 | A PROCESS FOR THE PREPARATION OF GLUCAGON | BIOCON LIMITED (IN) | 2024-08-02 | — | — | WO | claimed |
| US-20260042810-A1 | A PROCESS FOR THE PREPARATION OF GLUCAGON | BIOCON LTD (IN) | 2026-02-12 | — | — | US | disclosed |
| EP-4655312-A1 | A PROCESS FOR THE PREPARATION OF GLUCAGON | Biocon Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024157198-A1 | A PROCESS FOR THE PREPARATION OF GLUCAGON | BIOCON LIMITED (IN) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042810-A1 | A PROCESS FOR THE PREPARATION OF GLUCAGON | IAPP, GLP1R, GCG | NMBR 2449/4885SIRT2 439/4885REN 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.